8-KExhibits & Filings

WELLS FARGO & COMPANY/MN 8-K Report, Exhibit Filing (Dec 14, 2017)

Filed December 14, 2017For Securities:WFCWFC-PDWFC-PCWFC-PYWFC-PAWFC-PLWFCNPWFC-PZ

Summary

Wells Fargo & Company/MN (WFC) filed an 8-K on December 14, 2017, to report the issuance of new Medium-Term Notes, Series K. These notes are principal-at-risk securities, meaning the return is tied to the performance of specific underlying assets, in this case, the common stock of Celgene Corporation and Gilead Sciences, Inc. The notes are due to mature on December 16, 2024, and the return is linked to the *lowest performing* of the two stocks, introducing a specific risk profile for investors. The primary purpose of this filing is to include the official documentation for these notes, specifically the form of the note itself and the legal opinion from Faegre Baker Daniels LLP. Investors should note that this filing does not represent a change in financial performance or a new business development for Wells Fargo itself, but rather details a structured financial product offered by the company.

Key Highlights

  • 1Wells Fargo issued new "Medium-Term Notes, Series K" with a maturity date of December 16, 2024.
  • 2These are "Principal at Risk Securities", meaning potential loss of principal exists.
  • 3The notes' performance is linked to the *lowest performing* of Celgene Corporation and Gilead Sciences, Inc. common stock.
  • 4The filing includes the official form of the Note document.
  • 5A legal opinion from Faegre Baker Daniels LLP regarding the Notes is included as an exhibit.
  • 6The filing also includes the consent of Faegre Baker Daniels LLP.

Frequently Asked Questions

These are a type of structured financial product offered by Wells Fargo. They are "Principal at Risk Securities," meaning investors could lose a portion or all of their principal investment. The return on these notes is directly tied to the performance of the common stock of Celgene Corporation and Gilead Sciences, Inc.

The return is based on the performance of the *lowest performing* of the common stock of Celgene Corporation and Gilead Sciences, Inc. This means if one stock performs poorly, it can negatively impact or negate the returns from the other stock.

The notes are due to mature on December 16, 2024.

No, this 8-K filing is primarily to report the issuance of a specific financial product (the Notes) and to provide the associated legal and documentation exhibits. It does not report on the company's overall financial performance or strategic shifts.